pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 6·1 min read
save

CMS proposes rule to slash Medicare 340B drug payments by over a third

Jul 6, 2026·read at Endpoints ↗RegulatoryNegative

CMS announced a proposed rule that would reduce the rates Medicare uses to reimburse hospitals for drugs purchased through the 340B program.

The reduction would be more than one-third, effectively reviving a similar policy that was introduced during the first Trump administration.

The change could lower hospital revenues from the 340B program and may affect patient access to discounted medicines, according to industry observers.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “CMS proposes 340B cuts”

read at Endpoints ↗
75 words · retrieved Jul 6
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoExclusive: Astellas partners with Boston ‘miniproteins’ startupEndpoints
  • 2h agoRapport says drug it licensed from J&J clears Phase 2 bipolar mania studyEndpoints
  • 18h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 18h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 20h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints